

108291

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

SEARCH REQUEST FORM

Requestor's

Name:

Audet, M.

Serial

Number:

09/736076

Date:

11-14-03

Phone:

305-5039

Art Unit:

1654

11D04

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

Seq. IDs 15-19

STAFF USE ONLY

Date completed: 11-14-03

Searcher:

Beverly 4999f

Terminal time:

20 23

Elapsed time:

CPU time:

Total time:

Number of Searches:

Number of Databases:

Search Site

STIC

CM-1

Pre-S

Type of Search

N.A. Sequence

A.A. Sequence

Structure

Bibliographic

Vendors

IG

STN

Dialog

APS

Geninfo

SDC

DARC/Questel

Other CGN

Aud t, Maury

Subject: 09736076-Search of 5 Peptides

In the above application, please search the following 5 sequences: SEQ ID NOS: 15, 16, 17, 18, and 19 (including pending DB's RAPM, RAPN).

Thanks.

Maury

11/20/94

703-305-5039.

Audet, M.
091736076

09/736076

103456789

L1 FILE 'REGISTRY' ENTERED AT 14:26:52 ON 14 NOV 2003
31 S MLLG[KR]PPF | LGRPPFETS/SQSP

L2 FILE 'HCAPLUS' ENTERED AT 14:28:05 ON 14 NOV 2003
18 S L1

L2 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:765147 HCAPLUS
DOCUMENT NUMBER: 139:241380
TITLE: Expressed sequence tags from cDNA libraries
derived from human mRNAs having intact 5' ends
and their encoded secreted proteins
INVENTOR(S): Tanaka, Hiroaki; Dumas Milne, Edwards
Jean-Baptiste; Giordano, Jean-Yves; Jobert,
Severin; Bejanin, Stephane
PATENT ASSIGNEE(S): Genset, Fr.
SOURCE: Can. Pat. Appl., 163 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2343602	AA	20011018	CA 2001-2343602	20010417
CA 2343602	AA	20011018	CA 2001-2343602	20010417

PRIORITY APPLN. INFO.: US 2000-197873P P 20000418
CA 2001-2343602 A 20010417

AB The sequences of 5' ESTs and consensus contigated 5' ESTs derived from cDNA libraries derived from mRNAs having intact 5' ends are disclosed. The 5' ESTs and consensus contigated 5' ESTs may be used to obtain cDNAs and genomic DNAs corresponding to the 5' ESTs and consensus contigated 5' ESTs. The 5' ESTs and consensus contigated 5' ESTs may also be used in diagnostic, forensic, gene therapy, and chromosome mapping procedures. Upstream regulatory sequences may also be obtained using the 5' ESTs and consensus contigated 5' ESTs. The 5' ESTs and consensus contigated 5' ESTs may also be used to design expression vectors and secretion vectors. [This abstract record is one of thirteen records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT **599342-26-4**
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(amino acid sequence; expressed sequence tags from cDNA libraries derived from human mRNAs having intact 5' ends and their encoded secreted proteins)

L2 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:447168 HCAPLUS
DOCUMENT NUMBER: 139:227956
TITLE: Cell cycle dependent expression of Plk1 in
synchronized porcine fetal fibroblasts
AUTHOR(S): Anger, Martin; Kues, Wilfried A.; Klima, Jiri;
Mielenz, Manfred; Kubelka, Michal; Motlik, Jan;
Esner, Milan; Dvorak, Petr; Carnwath, Joseph W.;

09/736076

CORPORATE SOURCE: Niemann, Heiner
Institute of Animal Physiology and Genetics,
Libechov, Czech Rep.
SOURCE: Molecular Reproduction and Development (2003),
65(3), 245-253
CODEN: MREDEE; ISSN: 1040-452X
PUBLISHER: Wiley-Liss, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Enzymes of the Polo-like kinase (Plk) family are active in the
pathways controlling mitosis in several species. We have cloned
cDNA fragments of the porcine homologs of Plk1, Plk2, and Plk3
employing fetal fibroblasts as source. All three partial cDNAs
showed high sequence homol. with their mouse and human counterparts
and contained the Polo box, a domain characteristic for all Polo
kinases. The expression levels of Plk1 mRNA at various points of
the cell cycle in synchronized porcine fetal fibroblasts were
analyzed by both RT-PCR and the RNase protection assay. Plk1 mRNA
was barely detectable in G0 and G1, increased during S phase and
peaked after the G2/M transition. A monoclonal antibody was
generated against an in vitro expressed porcine Plk1-protein
fragment and used to detect changes in Plk1 expression at the
protein level. Plk1 protein was first detected by immunoblotting at
the beginning of S phase and was highest after the G2/M transition.
In summary, the Plk1 expression pattern in the pig is similar to
that reported for other species. The absence of Plk1 mRNA and
protein appears to be a good marker for G0/G1 and thus for the
selection of donor cells for nuclear transfer based somatic cloning.
IT **481546-49-0**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(amino acid sequence; cDNA sequences of Polo-like kinase (Plk1,
Plk2, and Plk3) sequence homologs of pig and cell cycle dependent
expression of Plk1 in synchronized porcine fetal fibroblasts)
REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L2 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:334543 HCAPLUS
DOCUMENT NUMBER: 138:350479
TITLE: Protein and cDNA sequences of human protein
kinase/protein phosphatase sequence homologs
INVENTOR(S): Ota, Toshio; Isogai, Takao; Nishikawa, Tetsuo;
Hayashi, Koji; Otsuka, Kaoru; Yamamoto,
Jun-ichi; Ishii, Shizuko; Sugiyama, Tomoyasu;
Wakamatsu, Ai; Nagai, Keiichi; Otsuki, Tetsuji;
Funahashi, Shin-ichi; Senoo, Chiaki; Nezu,
Jun-ichi
PATENT ASSIGNEE(S): Japan
SOURCE: U.S. Pat. Appl. Publ., 113 pp., Cont.-in-part of
Appl. No. PCT/JP00/05060.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

09/736076

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003082776	A1	20030501	US 2002-59585	20020129
JP 2002171977	A2	20020618	JP 2000-196309	20000626
WO 2001009345	A1	20010208	WO 2000-JP5060	20000728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
WO 2001009319	A1	20010208	WO 2000-JP5065	20000728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CL, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1205549	A1	20020515	EP 2000-948282	20000728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.:

JP 1999-248036	A	19990729
US 1999-159590P	P	19991018
JP 2000-118776	A	20000111
US 2000-183322P	P	20000217
JP 2000-183767	A	20000502
WO 2000-JP5060	A2	20000728
WO 2000-JP5065	W	20000728

AB The invention provides protein and cDNA sequences of human proteins having the kinase and/or phosphatase-like structure from clones which had been isolated and the structures thereof had been determined in the Helix Research Institute (helix clones; Japanese Patent Application Number 2000-183767) was conducted. Twelve novel genes were provided by carrying out homol. search for all the helix clones by using the amino acid sequences of known kinases and phosphatases as queries. The genes are expected to be involved in intracellular signal transduction. The physiol. functions of the inventive genes can be tested by using reporter gene assay systems capable of detecting signal transduction. The proteins of the present invention are useful as target mols. in drug discovery and in the development of new pharmaceuticals.

IT 518362-19-1P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation)

(amino acid sequence; protein and cDNA sequences of human protein kinase/protein phosphatase sequence homologs)

L2 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
 ACCESSION NUMBER: 2003:97986 HCAPLUS

Searcher : Shears 308-4994

09/736076

DOCUMENT NUMBER: 138:147705
TITLE: Protein and cDNA sequences of human protein kinase SAK and use in modulation of cellular proliferation for treatment of cancer
INVENTOR(S): Hitoshi, Yasumichi; Demo, Susan; Jenkins, Yonchu
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003027756	A1	20030206	US 2001-26021	20011221
WO 2003012055	A2	20030213	WO 2002-US24312	20020731
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-309632P P 20010801
US 2001-26021 A 20011221

AB The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small mol. chemical compns., antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compns. in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

IT **496831-29-9**

RL: PRP (Properties)
(unclaimed sequence; protein and cDNA sequences of human protein kinase SAK and use in modulation of cellular proliferation for treatment of cancer)

L2 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:55959 HCAPLUS

DOCUMENT NUMBER: 138:84325

TITLE: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

AUTHOR(S): Strausberg, Robert L.; Feingold, Elise A.; Grouse, Lynette H.; Derge, Jeffery G.; Klausner, Richard D.; Collins, Francis S.; Wagner, Lukas;

09/736076

Shenmen, Carolyn M.; Schuler, Gregory D.;
Altschul, Stephen F.; Zeeberg, Barry; Buetow,
Kenneth H.; Schaefer, Carl F.; Bhat, Narayan K.;
Hopkins, Ralph F.; Jordan, Heather; Moore, Troy;
Max, Steve I.; Wang, Jun; Hsieh, Florence;
Diatchenko, Luda; Marusina, Kate; Farmer, Andrew
A.; Rubin, Gerald M.; Hong, Ling; Stapleton,
Mark; Soares, M. Bento; Bonaldo, Maria F.;
Casavant, Tom L.; Scheetz, Todd E.; Brownstein,
Michael J.; Usdin, Ted B.; Toshiyuki, Shiraki;
Carninci, Piero; Prange, Christa; Raha, Sam S.;
Loquellano, Naomi A.; Peters, Garrick J.;
Abramson, Rick D.; Mullahy, Sara J.; Bosak,
Stephanie A.; McEwan, Paul J.; McKernan, Kevin
J.; Malek, Joel A.; Gunaratne, Preethi H.;
Richards, Stephen; Worley, Kim C.; Hale, Sarah;
Garcia, Angela M.; Gay, Laura J.; Hulyk, Stephen
W.; Villalon, Debbie K.; Muzny, Donna M.;
Sodergren, Erica J.; Lu, Xiuhua; Gibbs, Richard
A.; Fahey, Jessica; Helton, Erin; Kettelman,
Mark; Madan, Anuradha; Rodrigues, Stephanie;
Sanchez, Amy; Whiting, Michelle; Madan, Anup;
Young, Alice C.; Shevchenko, Yuriy; Bouffard,
Gerard G.; Blakesley, Robert W.; Touchman,
Jeffrey W.; Green, Eric D.; Dickson, Mark C.;
Rodriguez, Alex C.; Grimwood, Jane; Schmutz,
Jeremy; Myers, Richard M.; Butterfield, Yaron S.
N.; Krzywinski, Martin I.; Skalska, Ursula;
Smailus, Duane E.; Schnerch, Angelique; Schein,
Jacqueline E.; Jones, Steven J. M.; Marra, Marco
A.

CORPORATE SOURCE:

National Cancer Institute, NIH, Bethesda, MD,
20892-2580, USA

SOURCE:

Proceedings of the National Academy of Sciences
of the United States of America (2002), 99(26),
16899-16903

CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER:

National Academy of Sciences

DOCUMENT TYPE:

Journal

LANGUAGE:

English

AB The National Institutes of Health Mammalian Gene Collection (MGC)
Program is a multiinstitutional effort to identify and sequence a
cDNA clone containing a complete ORF for each human and mouse gene.
ESTs were generated from libraries enriched for full-length cDNAs
and analyzed to identify candidate full-ORF clones, which then were
sequenced to high accuracy. The MGC has currently sequenced and
verified the full ORF for a nonredundant set of >9000 human and
>6000 mouse genes. Candidate full-ORF clones for an addnl. 7800
human and 3500 mouse genes also have been identified. All MGC
sequences and clones are available without restriction through
public databases and clone distribution networks. [This abstract
record is one of eleven records for this document necessitated by
the large number of index entries required to fully index the document
and publication system constraints.]

IT **483718-42-9**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(amino acid sequence; generation and initial anal. of more than

09/736076

15,000 full-length human and mouse cDNA sequences)

L2 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:55946 HCAPLUS

DOCUMENT NUMBER: 138:84320

TITLE: Generation and initial analysis of more than
15,000 full-length human and mouse cDNA
sequences

AUTHOR(S): Strausberg, Robert L.; Feingold, Elise A.;
Grouse, Lynette H.; Derge, Jeffery G.; Klausner,
Richard D.; Collins, Francis S.; Wagner, Lukas;
Shenmen, Carolyn M.; Schuler, Gregory D.;
Altschul, Stephen F.; Zeeberg, Barry; Buetow,
Kenneth H.; Schaefer, Carl F.; Bhat, Narayan K.;
Hopkins, Ralph F.; Jordan, Heather; Moore, Troy;
Max, Steve I.; Wang, Jun; Hsieh, Florence;
Diatchenko, Luda; Marusina, Kate; Farmer, Andrew
A.; Rubin, Gerald M.; Hong, Ling; Stapleton,
Mark; Soares, M. Bento; Bonaldo, Maria F.;
Casavant, Tom L.; Schéetz, Todd E.; Brownstein,
Michael J.; Usdin, Ted B.; Toshiyuki, Shiraki;
Carninci, Piero; Prange, Christa; Raha, Sam S.;
Loquellano, Naomi A.; Peters, Garrick J.;
Abramson, Rick D.; Mullahy, Sara J.; Bosak,
Stephanie A.; McEwan, Paul J.; McKernan, Kevin
J.; Malek, Joel A.; Gunaratne, Preethi H.;
Richards, Stephen; Worley, Kim C.; Hale, Sarah;
Garcia, Angela M.; Gay, Laura J.; Hulyk, Stephen
W.; Villalon, Debbie K.; Muzny, Donna M.;
Sodergren, Erica J.; Lu, Xiuhua; Gibbs, Richard
A.; Fahey, Jessica; Helton, Erin; Kettelman,
Mark; Madan, Anuradha; Rodrigues, Stephanie;
Sanchez, Amy; Whiting, Michelle; Madan, Anup;
Young, Alice C.; Shevchenko, Yuriy; Bouffard,
Gerard G.; Blakesley, Robert W.; Touchman,
Jeffrey W.; Green, Eric D.; Dickson, Mark C.;
Rodriguez, Alex C.; Grimwood, Jane; Schmutz,
Jeremy; Myers, Richard M.; Butterfield, Yaron S.
N.; Krzywinski, Martin I.; Skalska, Ursula;
Smailus, Duane E.; Schnerch, Angelique; Schein,
Jacqueline E.; Jones, Steven J. M.; Marra, Marco
A.

CORPORATE SOURCE: Mammalian Gene Collection (MGC) Program Team,
National Cancer Institute, NIH, Bethesda, MD,
20892-2580, USA

SOURCE: Proceedings of the National Academy of Sciences
of the United States of America (2002), 99(26),
16899-16903

CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The National Institutes of Health Mammalian Gene Collection (MGC)
Program is a multiinstitutional effort to identify and sequence a
cDNA clone containing a complete ORF for each human and mouse gene.
ESTs were generated from libraries enriched for full-length cDNAs
and analyzed to identify candidate full-ORF clones, which then were
sequenced to high accuracy. The MGC has currently sequenced and

09/736076

verified the full ORF for a nonredundant set of >9000 human and >6000 mouse genes. Candidate full-ORF clones for an addnl. 7800 human and 3500 mouse genes also have been identified. All MGC sequences and clones are available without restriction through public databases and clone distribution networks. [This abstract record is one of eleven records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

IT 480062-88-2

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; generation and initial anal. of more than 15,000 full-length human and mouse cDNA sequences)

L2 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:889007 HCAPLUS

DOCUMENT NUMBER: 138:347

TITLE: Sequences of genetic markers for evaluating estrogenic activity

INVENTOR(S): Barbosa, Miguel S.; Brady, Helen A.; Chan, Kyle W. H.; Pardinas, Jose R.

PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002093124	A2	20021121	WO 2002-US14597	20020510
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2003054332 A1 20030320 US 2001-853544 20010510

PRIORITY APPLN. INFO.: US 2001-853544 A 20010510

AB Methods are provided for evaluating estrogenic and antiestrogenic effects of candidate therapeutic agents. Such methods are generally based on assays to detect modulation of estrogen-regulated marker expression in one or more specific cell types. Agents identified using such methods may be used, for example, in the prevention and treatment of diseases such as osteoporosis, cardiovascular disease and cancer. In addition, the gene discovery approaches discussed have identified a using gene profile for estrogen regulation in vascular endothelial cells. This gene profile will allow characterization of the effects of potential SERMs in the cardiovascular system this gene profile and the assays established with these genes will enable more extensive evaluation of tissue specific properties of SERM compds. and provide a better understanding of cardiovascular effects

09/736076

of SERMs.
IT **402712-46-3**
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(amino acid sequence; sequences of genetic markers for evaluating
estrogenic activity)

L2 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:616256 HCAPLUS
DOCUMENT NUMBER: 137:181594
TITLE: Dominant-negative variants of human protein
kinases that inhibit the phosphorylation
activity of their active enzyme isoforms
INVENTOR(S): Levine, Zurit; Bernstein, Jeanne
PATENT ASSIGNEE(S): Compugen Ltd., Israel
SOURCE: U.S. Pat. Appl. Publ., 170 pp., Cont.-in-part of
U.S. Ser. No. 724,676.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2002110811	A1	20020815	US 2001-771161	20010126
PRIORITY APPLN. INFO.:			IL 2000-135619 A	20000512
			IL 2000-136776 A	20000615
			US 2000-724676 A2	20001128

AB The present invention concerns 91 nucleic acid sequences and amino
acid sequences of variants of various human kinases, i.e. of
sequences which inhibit activity of kinases in a dominant manner.
The variants lack a domain or region required for phosphorylation,
and thus may be dominant-neg. kinases obtained by alternative
splicing of known original sequences of the kinase genes. The novel
dominant-neg. kinase variants of the invention are not merely
artificially truncated forms, fragments or mutations of known genes,
but rather novel sequences which naturally occur within the body of
individuals. The invention also concerns pharmaceutical compns. and
detection methods using these sequences.

IT **449226-29-3**
RL: PRP (Properties)
(unclaimed protein sequence; dominant-neg. variants of human
protein kinases that inhibit the phosphorylation activity of
their active enzyme isoforms)

L2 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:521988 HCAPLUS
DOCUMENT NUMBER: 137:74472
TITLE: Human cDNAs for NF-kB activating proteins
INVENTOR(S): Matsuda, Akio; Honda, Goichi; Muramatsu, Shuji;
Nagano, Yukiko
PATENT ASSIGNEE(S): Asahi Kasei Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 841 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2

09/736076

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002053737	A1	20020711	WO 2001-JP11389	20011225
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1354950	A1	20031022	EP 2001-272530	20011225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003170719	A1	20030911	US 2002-42211	20020107
PRIORITY APPLN. INFO.:				
JP 2000-402288 A 20001228				
JP 2001-88912 A 20010326				
JP 2001-254018 A 20010824				
US 2000-258315P P 20001228				
US 2001-278640P P 20010326				
US 2001-314385P P 20010824				
US 2001-24298 A2 20011221				
WO 2001-JP11389 W 20011225				
AB	Novel human proteins having an NF-kB activating effect, cDNAs, recombinant expression, use in diagnosis and drug screening, are disclosed. Use of antibodies, ribozymes, or antisense oligonucleotides for those cDNAs and proteins for treatment of inflammation, autoimmune disease, infection, cancer, bone disease, AIDS, neurodegenerative disease, or ischemic disease, is claimed. From a cDNA library prepared from human lung fibroblasts, cDNAs encoding proteins having an effect of activating NF-kB were cloned and their DNA and amino acid sequence deduced therefrom were determined			
IT	440684-40-2P , Protein (human NF-kB activating) RL: ARU (Analytical role, unclassified); BPN (Biosynthetic preparation); BUU (Biological use, unclassified); DGN (Diagnostic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses) (amino acid sequence; human cDNAs for NF-kB activating proteins)			
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT				
L2	ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN			
ACCESSION NUMBER:	2002:509654 HCAPLUS Correction of: 2002:10496			
DOCUMENT NUMBER:	137:58696 Correction of: 136:49428			
TITLE:	Human nucleic acids and their encoded proteins and antibodies for the diagnosis and therapy of ovarian cancer			
INVENTOR(S):	Birse, Charles E.; Rosen, Craig A.			
PATENT ASSIGNEE(S):	Human Genome Sciences, Inc., USA			
SOURCE:	PCT Int. Appl., 2922 pp.			

09/736076

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 91
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000677	A1	20020103	WO 2001-US18569	20010607
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001041411	A5	20010820	AU 2001-41411	20010208
PRIORITY APPLN. INFO.:			US 2000-209467P	P 20000607
			US 2000-241221P	P 20001020
			US 2000-241786P	P 20001020

AB The present invention relates to novel ovarian cancer-related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "ovarian cancer antigens", and the use of such antigens for detecting disorders of the ovary, particularly the presence of ovarian cancer and ovarian cancer metastases. More specifically, 2185 isolated ovarian cancer-associated cDNA mols. are provided encoding novel polypeptides: Novel ovarian cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human ovarian cancer-associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the ovary, including ovarian cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compns. for inhibiting the production and function of the polypeptides of the present invention. The Sequence Listing was provided as an electronic file, but was not made available in the release of this patent.

IT **439729-90-5P**

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino acid sequence; human nucleic acids and their encoded proteins and antibodies for the diagnosis and therapy of ovarian cancer)

L2 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:315483 HCAPLUS
DOCUMENT NUMBER: 136:335268
TITLE: Short peptides which selectively modulate the

09/736076

INVENTOR(S): activity of serine/threonine kinases
Ben-sasson, Shmuel A.
PATENT ASSIGNEE(S): The Children's Medical Center Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of
U. S. 6,174,993.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002049301	A1	20020425	US 2000-736076	20001213
US 6174993	B1	20010116	US 1997-861338	19970521

PRIORITY APPLN. INFO.: ~~US 1997-861338~~ A2 19970521
OTHER SOURCE(S): MARPAT 136:335268
AB Peptides are disclosed which are peptide derivs. of the HJ loop of a serine/threonine kinase. The peptides can modulate the activity of the serine/threonine kinase. Also disclosed are methods of modulating the activity of a serine/threonine kinase in a subject by administering one of the peptides of the invention. The peptides can be used for the treatment of a wide variety of diseases.
IT ~~216489-73-5P~~ ~~216489-75-7P~~ 16
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses).
(peptide modulators of serine/threonine kinases)
IT ~~416847-00-2~~ ~~416847-01-3~~ ~~416847-41-1~~
~~416847-48-8~~
RL: PRP (Properties)
(unclaimed sequence; short peptides which selectively modulate the activity of serine/threonine kinases)

L2 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:746842 HCAPLUS
DOCUMENT NUMBER: 136:51338
TITLE: Cloning and characterization of Plx2 and Plx3, two additional polo-like kinases from Xenopus laevis
AUTHOR(S): Duncan, Peter I.; Pollet, Nicolas; Niehrs, Christof; Nigg, Erich A.
CORPORATE SOURCE: Department of Cell Biology, Max Planck Institute for Biochemistry, Martinsried, D-82152, Germany
SOURCE: Experimental Cell Research (2001), 270(1), 78-87
CODEN: ECREAL; ISSN: 0014-4827
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Members of the family of Polo-like kinases are implicated in the regulation of cell cycle progression in all eukaryotes. In Xenopus laevis, only 1 member of this family, Plx1, has previously been described. Here we report the cloning and characterization of X. laevis Plx2 and Plx3, the likely homologs of mammalian Plk2 (Snk) and Plk3 (Fnk/Prk), resp. RNA expression studies indicate that all 3 Xenopus Plks are present in both oocytes and unfertilized eggs. Further anal. by in situ hybridization revealed that Plx1 RNA is ubiquitously expressed in early embryos, but shows more restricted

09/736076

expression at later stages. In contrast, Plx2 and Plx3 expression is highly restricted in both early and late-stage embryos. Using Plx-specific antisera, Plx1 and Plx3 polypeptides could readily be detected on immunoblots of oocyte and egg exts. Both Plx1 and Plx3 protein levels remained virtually constant during oocyte maturation. However, whereas Plx1 is more active in M phase than in I phase, Plx3 protein and activity levels remained constant upon release of meiotic metaphase II-arrested egg exts. into interphase. Finally, microinjection of in vitro-transcribed RNAs for Plx1, Plx2, and Plx3 increased the rate of progesterone-induced oocyte maturation, and concomitantly, all 3 kinases became activated. Conversely, overexpression of the corresponding catalytically inactive kinases delayed maturation. This suggests that, at least in oocytes, all 3 kinases may be regulated by similar mechanisms, and they may also share common substrates. However, the strikingly restricted pattern of expression of Plx2 and Plx3 observed in embryos strongly suggests that individual Plk family members perform at least partly distinct functions at later stages of development. (c) 2001 Academic Press.

IT 382721-00-8

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(amino acid sequence; cloning and characterization of two addnl. polo-like kinases from frog eggs and embryos)

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:629826 HCAPLUS

DOCUMENT NUMBER: 136:211644

TITLE: Identification of the human homologue of the early-growth response gene Snk, encoding a serum-inducible kinase

AUTHOR(S): Liby, Karen; Wu, Huiyun; Ouyang, Bin; Wu, Shecao; Chen, Jie; Dai, Wei

CORPORATE SOURCE: Department of Cell Biology, University of Cincinnati College of Medicine, USA

SOURCE: DNA Sequence (2001), 11(6), 527-533
CODEN: DNSEES; ISSN: 1042-5179

PUBLISHER: Harwood Academic Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Murine serum inducible kinase (mSnk) was recently cloned and characterized as an early-growth response gene involved in cell proliferation. Here we report the isolation and characterization of its human homolog, named hSnk. Sequence comparison shows that hSnk is highly conserved and its deduced protein sequence shares a significant amino acid identity with mSnk and rSnk proteins, as well as with other polo family kinase gene products. A survey of hSnk expression reveals that while a wide variety of human tissues express a low to moderate level of hSnk transcripts, fetal tissues, testis, and spleen express the most abundant hSnk transcripts. In addition, serum stimulation rapidly induces hSnk expression in fibroblast cells, reaching the peak level of induction within one hour post treatment. Considering that Plk and Prk, two other known human polo-family kinases, control cell cycle checkpoint and cell cycle progression, our current observations suggest that hSnk may also play an important role in cells undergoing rapid cell division

09/736076

or having a high mitotic index.

IT **402712-46-3**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)

(amino acid sequence; identification of the human homolog of the
early-growth response gene Snk, encoding a serum-inducible
kinase)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE
FOR THIS RECORD. ALL CITATIONS AVAILABLE
IN THE RE FORMAT

L2 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:106056 HCAPLUS

DOCUMENT NUMBER: 134:188986

TITLE: Human expressed sequence tags and primers for
synthesizing full-length cDNAs

INVENTOR(S): Ota, Toshio; Isogai, Takao; Nishikawa, Tetsuo;
Hayashi, Kohji; Saito, Kaoru; Yamamoto, Junichi;
Ishii, Shizuko; Sugiyama, Tomoyasu; Wakamatsu,
Ai; Nagai, Keiichi; Otsuki, Tetsuji

PATENT ASSIGNEE(S): Helix Research Institute, Japan

SOURCE: Eur. Pat. Appl., 2527 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1074617	A2	20010207	EP 2000-116126	20000728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002171977	A2	20020618	JP 2000-196309	20000626
EP 1205549	A1	20020515	EP 2000-948282	20000728
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2002191363	A2	20020709	JP 2000-280990	20000728
PRIORITY APPLN. INFO.:				
			JP 1999-248036	A 19990729
			JP 1999-300253	A 19990827
			JP 2000-118776	A 20000111
			JP 2000-183767	A 20000502
			JP 2000-241899	A 20000609
			US 1999-159590P	P 19991018
			US 2000-183322P	P 20000217
			WO 2000-JP5065	W 20000728

AB Primers for synthesizing full-length cDNAs and their use are
provided. The invention provides 5'-end sequences for 5602 partial
cDNA sequences (expressed sequence tags, ESTs) and 3'-end sequences
for 4970 of these clones. Furthermore, primers for synthesizing the
full-length cDNA have been provided to clarify the function of the
protein encoded by the cDNA. The full-length cDNA sequences s of
the present invention containing the translation start site provides
information useful for analyzing the functions of the proteins.
Tissue- and cell-specific expression patterns are also provided.
[This abstract record is one of 6 records for this patent necessitated
by the large number of index entries required to fully index the
document and publication system constraints.]

09/736076

IT **326937-52-4**, Protein (human clone PLACE1011923)
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(amino acid sequence; human expressed sequence tags and primers
for synthesizing full-length cDNAs)

L2 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:139942 HCAPLUS
DOCUMENT NUMBER: 130:192783
TITLE: Cloning and cDNA sequence of human
serum-inducible kinase Snk
INVENTOR(S): Anderson, Karen M.; Jackson, Jeffrey R.;
Hansbury, Michael J.; Nerurkar, Sandhya S.;
Roshak, Amy K.; Bouzyk, Mark
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909146	A1	19990225	WO 1998-US17248	19980820
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6063609	A	20000516	US 1998-136282	19980820
EP 1007645	A1	20000614	EP 1998-942152	19980820
R: BE, CH, DE, DK, FR, GB, IT, LI, NL				
JP 2001514882	T2	20010918	JP 2000-509813	19980820
US 6245544	B1	20010612	US 2000-505744	20000216
PRIORITY APPLN. INFO.:			US 1997-56112P	P 19970820
			US 1998-136282	A3 19980820
			WO 1998-US17248	W 19980820

AB The serum-inducible kinase (Snk) polypeptides and polynucleotides
and methods for producing such polypeptides by recombinant
techniques are disclosed. The nucleotide sequence of human Snk is a
cDNA sequence and comprises an open reading frame encoding a
polypeptide of 685 amino acids that is structurally related to other
proteins of the Polo-like kinase family and having homol. and/or
structural similarity with murine serum-inducible kinase. The gene
of the present invention maps to human chromosome
5d12.1-q13.2/D5S491-D5S427. Also disclosed are methods for
utilizing Serum Inducible Kinase (Snk) polypeptides and
polynucleotides in therapy, and diagnostic assays for such.

IT **220748-32-3P**
RL: BPN (Biosynthetic preparation); PRP (Properties); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(amino acid sequence; cloning and cDNA sequence of human
serum-inducible kinase Snk)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN
THE RE FORMAT

L2 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN

09/736076

ACCESSION NUMBER: 1999:9924 HCAPLUS
DOCUMENT NUMBER: 130:77973
TITLE: Disease associated protein kinases of human and
their cDNA sequences
INVENTOR(S): Bandman, Olga; Hillman, Jennifer L.; Corley,
Neil C.; Guegler, Karl J.; Lal, Preeti; Goli,
Surya K.; Shah, Purvi
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 9858052	A2	19981223	WO 1998-US12813	19980619
WO 9858052	A3	19990610		
W:	AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5885803	A	19990323	US 1997-878989	19970619
AU 9881547	A1	19990104	AU 1998-81547	19980619
EP 1007692	A2	20000614	EP 1998-931407	19980619
R:	BE, DE, ES, FR, GB, IT, NL			
US 6207148	B1	20010327	US 1999-272796	19990319
US 2003170219	A1	20030911	US 2001-769970	20010124
PRIORITY APPLN. INFO.:			US 1997-878989 A2	19970619
			WO 1998-US12813 W	19980619
			US 1999-272796 A3	19990319

AB The invention provides human disease associated protein kinases and polynucleotides (collectively designated DAPK) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing and treating disorders associated with expression of human disease associated protein kinases. The amino acid sequences and cDNA sequences of some human disease-associated protein kinases are presented.

IT **218611-29-1**

RL: ANT (Analyte); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(amino acid sequence; disease associated protein kinases of human and their cDNA sequences)

L2 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:790656 HCAPLUS
DOCUMENT NUMBER: 130:22236
TITLE: Short peptides which selectively modulate the
activity of serine/threonine kinases
INVENTOR(S): Ben-Sasson, Shmuel A.
PATENT ASSIGNEE(S): The Children's Medical Center Corp., USA; Yisum
Research Development Company of the Hebrew
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2

09/736076

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9853050	A2	19981126	WO 1998-US10319	19980520
WO 9853050	A3	19990225		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6174993	B1	20010116	US 1997-861338	19970521
AU 9875833	A1	19981211	AU 1998-75833	19980520
AU 734642	B2	20010621		
EP 983346	A2	20000308	EP 1998-923571	19980520
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002500649	T2	20020108	JP 1998-550580	19980520
US 2002028772	A1	20020307	US 2000-735274	20001211
US 2003004103	A1	20030102	US 2001-12035	20011211
PRIORITY APPLN. INFO.:			US 1997-861338	A2 19970521
			WO 1998-US10319	W 19980520
			US 2000-735274	A2 20001211
AB	<p>Disclosed are peptides which are peptide derivs. of the HJ loop of a serine/threonine kinase. Modified peptides derivs. are provided from the modified sequence or subsequence of the HJ loop of such kinases as RAF, cAMP-dependent kinase, protein kinase C, the G protein-coupled receptor kinases βARK1, βBARK2, GRK1 and GRKs4-6, calmodulin-dependent kinase, and Polo. The peptides can modulate the activity of the serine/threonine kinase. For example, peptide derivs. of the HJ loop of Raf and Polo inhibit the proliferation of bovine aortic cells and the transformed mouse cell lines MS1 and/or SVR cells in vitro at concns. as low as 10 μM. Further examples include (1) inhibition of the production of collagen by fetal lung fibroblasts by an HJ peptide deriv of activin/TGFβR and (2) morphol. changes in B16 melanoma cells by an HJ peptide derivative of integrin-linked kinase ILK. Also disclosed are methods of modulating the activity of a serine/threonine kinase in a subject by administering one of the peptides of the present invention.</p>			
IT	<p>216489-73-5 216489-75-7 216489-77-9 216489-79-1 216489-81-5 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (Polo kinase-derived; short peptides which selectively modulate the activity of serine/threonine kinases)</p>			
IT	<p>216490-49-2 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (SNK kinase-derived; short peptides which selectively modulate</p>			

09/736076

the activity of serine/threonine kinases)

L2 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:444118 HCAPLUS
DOCUMENT NUMBER: 119:44118
TITLE: Identification of an early-growth-response gene
encoding a novel putative protein kinase
AUTHOR(S): Simmons, Daniel L.; Neel, Benjamin G.; Stevens,
Ryan; Evett, Gary; Erikson, Raymond L.
CORPORATE SOURCE: Dep. Chem., Brigham Young Univ., Provo, UT,
84602, USA
SOURCE: Molecular and Cellular Biology (1992), 12(9),
4164-9
CODEN: MCEBD4; ISSN: 0270-7306
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Early-growth-response genes, also known as immediate-early genes,
play important roles in regulating cell proliferation. A new type
of early-growth-response gene product, a 77,811-Da putative
serine/threonine kinase, was identified which is highly inducible by
serum and phorbol ester. mRNA encoding this putative kinase is
markedly elevated within 1 h after treatment with mitogen, and this
induction is synergistically increased by cycloheximide.
Dexamethasone blocks serum induction of the kinase mRNA, as does
transformation by v-Ki-ras. The kinase mRNA was detected in mouse
brain, lung, and heart. This new putative kinase, called Snk, for
serum-inducible kinase, showed similarity in its proposed catalytic
domain to many other protein kinases; however, no other kinase
showed enough sequence similarity with Snk to suggest the existence
of a common function. Hence, Snk represents a new type of protein
kinase involved in the early mitogenic response whose activity is
transcriptionally and posttranscriptionally regulated.
IT **148466-70-0**
RL: PRP (Properties); BIOL (Biological study)
(amino acid sequence of, complete)

E1 THROUGH E25 ASSIGNED

FILE 'REGISTRY' ENTERED AT 14:29:04 ON 14 NOV 2003
L3 25 SEA FILE=REGISTRY ABB=ON PLU=ON (216489-73-5/BI OR
216489-75-7/BI OR 402712-46-3/BI OR 148466-70-0/BI OR
216489-77-9/BI OR 216489-79-1/BI OR 216489-81-5/BI OR
216490-49-2/BI OR 218611-29-1/BI OR 220748-32-3/BI OR
326937-52-4/BI OR 382721-00-8/BI OR 416847-00-2/BI OR
416847-01-3/BI OR 416847-41-1/BI OR 416847-48-8/BI OR
439729-90-5/BI OR 440684-40-2/BI OR 449226-29-3/BI OR
480062-88-2/BI OR 481546-49-0/BI OR 483718-42-9/BI OR
496831-29-9/BI OR 518362-19-1/BI OR 599342-26-4/BI)

L4 25 L1 AND L3

L4 ANSWER 1 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **599342-26-4** REGISTRY
CN Protein (human clone CA2343602-SEQID-15222 N-terminal fragment)
(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3220: PN: CA2343602 SEQID: 15222 claimed protein
CI MAN

09/736076

SQL 90

SEQ 1 MELKVGDFGL AARLEPLEHR RRTICGTPNY LSPEVLXKXG HGCEXSIWAL
51 GCVMYTMLLG RPPFETTKSQ RNLQVHKGNN VYNAILIAGS

====

HITS AT: 57-64

REFERENCE 1: 139:241380

L4 ANSWER 2 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN

RN **518362-19-1** REGISTRY

CN Protein (human clone C-PLACE1011923 protein kinase/protein
phosphatase sequence homolog) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 14: PN: US20030082776 SEQID: 14 claimed protein

CI MAN

SQL 469

SEQ 1 MELKVGDFGL AARLEPLEHR RRTICGTPNY LSPEVLNKQG HGCESDIWAL
51 GCVMYTMLLG RPPFETTNLK ETYRCIREAR YTMPSSLLAP AKHLIASMLS

====

101 KNPEDRPSLD DIIRHDFFLQ GFTPDLSSS CCHTVPDFHL SSPAKNFFKK
151 AAAALFGGKK DKARYIDTHN RVSKEDEDIY KLRHDLKKTS ITQQPSKHRT
201 DEELQPPTTT VARGTTPAVE NKQQIGDAIR MIVRGTLGSC SSSSECLEDS
251 TMGSVADTVA RVLRGLENM PEADCIPKEQ LSTSFQWVTK WVDYSNKYGF
301 GYQLSDHTVG VLFNNGAHMS LLPDKKTVHY YAELGQCSVF PATDAPEQFI
351 SQVTVLKYFS HYMEENLMDG GDLPSVTDIR RPRLYLLQWL KSDKALMMLF
401 NDGTFQVNFY HDHTKIIICS QNEEYLLTYI NEDRISTTFR LTTLLMSGCS
451 SELKNRMEYA LNMLLQRCN

HITS AT: 57-64

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:350479

L4 ANSWER 3 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN

RN **496831-29-9** REGISTRY

CN 5: PN: US20030027756 FIGURE: 2 unclaimed sequence (9CI) (CA INDEX
NAME)

CI MAN

SQL 400

SEQ 1 MELLRTITYQ PAASTKMCEQ ALGKGCGGDS KKKRPPQPPE ESQPPQSQAQ
51 VPPAAPHHHH HSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
151 DKENIYILLE YCSRSMMAHI LKARKVLTEP EVRYYLRLQIV SGLKYLHEQE
201 ILHRDLKLG N FINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
251 VLNKQGHGCE SDIWALGCV M YTMLLGRPPF ETTNLKET YR CIREARYTMP

=====

301 SLLAPAKHL IASMLSKNPE DRPSLD DIIR H DFFLQGFYP DRLSSSCCHT
351 VPDFWLSSPA KNFFKKAAAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH

HITS AT: 273-280

REFERENCE 1: 138:147705

L4 ANSWER 4 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN

RN **483718-42-9** REGISTRY

CN Serum-inducible kinase (mouse strain FVB/N clone MGC:7061

09/736076

IMAGE:3156743) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AAH34513

CN GenBank AAH34513 (Translated from: GenBank BC034513)

CI MAN

SQL 682

SEQ 1 MELLRTITYQ PAAGTKMCEQ ALGKACGGDS KKKRPQQPSE DGQPQAQVTP
51 AAPHHHHHHS HSGPEISRRII VDPTTGKRYC RGKVLGKGGF AKCYEMTDLT
101 NNKVYAAKII PHSRVAKPHQ REKIDKEIEL HRLHHKHVV QFYHYFEDKE
151 NIYILLEYCS RRSMAHILKA RKVLTEPEVR YYLRQIVSGL KYLHEQEILH
201 RDLKLGNFII NEAMELKVDG FGLAARLEPL EHRRTICGT PNYLSPEVLN
251 KQGHGCESDI WALGCVMYTM LLGRPPFETT NLKETYRCIR EARYTMPSSL
= =====
301 LAPAKHLIAS MLSKNPEDRP SLDDIIRHDF FLQGFTPDLR SSSCCHTVDP
351 FHLSSPAKNF FKAAAALFG GKDKARYND THNKVSKED DIYKLRHDLK
401 KVSITQQPSK HRADEEPQPP PTTVARSGTS AVENKQQIGD AIRMIVRGT
451 GSCSSSECL EDSTMGSVAD TVARVLRGCL ENMPEADCIP KEQLSTSFQW
501 VTKWVDYSNK YGFGYQLSDH TVGVLFNNGA HMSLLPDKKT VHYYAELGQC
551 SVFPATDAPE QFISQVTVLK YFSHYMEENL MDGGDLPSVT DIRRPRLYLL
601 QWLKSDKALM MLFNDGTFQV NFYHDHTKII ICNQSEYLL TYINEDRIST
651 TFRLTLLMS GCSLELKNRM EYALNMLLQR CN

HITS AT: 270-277

REFERENCE 1: 138:84325

L4 ANSWER 5 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN

RN **481546-49-0** REGISTRY

CN Protein (swine Polo-like kinase Plk2 sequence homolog fragment)
(9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AAK27154

CN GenBank AAK27154 (Translated from: GenBank AF348424)

CN Protein (Sus scrofa Polo-like kinase Plk2 sequence homolog fragment)

CI MAN

SQL 316

SEQ 1 PEVLNKQGHG CESDIWALGC VMYTMLLGRP PFETTNLKET YRCIREARYT
===== ==
51 MPSSLLAPAK HLIASMLSKN PEDRPSLDDI IRHEFFLQGF TPDLRSSSCC
101 HTVPDFHLSS PAKNFFKKA AALFGGKKDK ARYIDTHNRV SKEDEEIYKL
151 RHDLLKTSIT QQPSKHRTDE ELQPPTTTVA RSGTPAVENK QQIGDAIRMI
201 VRGTLGSCSS SSECLELSTM GSVADTVARV LRGLENMPE ADCIPKEQLS
251 TSFQWVTKWV DYSNKYGFY QLSDHTVGVL FNNGAHMSLL PDKKTVHYA
301 ELGQCSVFPA TDAPEQ

HITS AT: 25-32

REFERENCE 1: 139:227956

L4 ANSWER 6 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN

RN **480062-88-2** REGISTRY

CN (Protein for MGC:10589) (human clone MGC:10589 IMAGE:3831747) (9CI)
(CA INDEX NAME)

OTHER NAMES:

CN GenBank AAH13879

CN GenBank AAH13879 (Translated from: GenBank BC013879)

CI MAN

SQL 685

09/736076

SEQ 1 MELLRTITYQ PAASTKMCEQ ALGKGCAGDS KKKRPPQPPE ESQPPQSQAQ
51 VPPAAPHHHH HSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
151 DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRLQIV SGLKYLHEQE
201 ILHRDLKLGK FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
251 VLNKQGHGCE SDIWALGCVL YTMLLGRPPF ETTNLKETYR CIREARYTMP
=====

301 SLLAPAKHL IASMLSKNPE DRPSLDDIIR HDEFLQGFPT DRLSSSCCHT
351 VPDFHLSSPA KNFFKKAATA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH
401 DLKTSITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGDAIRMIVR
451 GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS
501 FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKTVHYAEL
551 GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL
601 YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR
651 ISTTFRLLTL LMSGCSSELK NRMEYALNML LQRCN

HITS AT: 273-280

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:84320

L4 ANSWER 7 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **449226-29-3** REGISTRY
CN 249: PN: US20020110811 SEQID: 249 unclaimed protein (9CI) (CA INDEX
NAME)
CI MAN
SQL 685

SEQ 1 MELLRTITYQ PAASTKMCEQ ALGKGCAGDS KKKRPPQPPE ESQPPQSQAQ
51 VPPAAPHHHH HSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
151 DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRLQIV SGLKYLHEQE
201 ILHRDLKLGK FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
251 VLNKQGHGCE SDIWALGCVL YTMLLGRPPF ETTNLKETYR CIREARYTMP
=====

301 SLLAPAKHL IASMLSKNPE DRPSLDDIIR HDEFLQGFPT DRLSSSCCHT
351 VPDFHLSSPA KNFFKKAATA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH
401 DLKTSITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGDAIRMIVR
451 GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS
501 FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKTVHYAEL
551 GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL
601 YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR
651 ISTTFRLLTL LMSGCSSELK NRMEYALNML LQRCN

HITS AT: 273-280

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:181594

L4 ANSWER 8 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **440684-40-2** REGISTRY
CN Protein (human NF-kB activating) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 39: PN: WO02053737 SEQID: 101 claimed protein
CI MAN
SQL 685

09/736076

SEQ 1 MELLRTITYQ PAASTKMCEQ ALGKGC GADS KKKRPPQPPE ESQPPQSQAQ
51 VPPAAPHHHH HSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
151 DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRLQIV SGLKYLHEQE
201 ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
251 VLNKQGHGCE SDIWALGCV M YTMLLGRPPF ETTNLKET YR CIREARYTMP
=====

301 SLLAPAKHL IASMLSKNPE DRPSLDDIIR HDEFFLQGFTP DRLSSSCCHT
351 VPDFHLSSPA KNFFKKA AAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH
401 DLKKT SITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGDAIRMIVR
451 GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS
501 FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKT VHYAEL
551 GQCSVFPATD APEQFISQVT VLKYF SHYME ENLMDGGDLP SVTDI RRPRL
601 YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR
651 ISTTFRLTTL LMSGCSSELK NRMEYALNML LQRCN

HITS AT: 273-280

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 137:74472

L4 ANSWER 9 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **439729-90-5** REGISTRY
CN Ovary-associated antigen (human clone HAOSM08 fragment) (9CI) (CA
INDEX NAME)
OTHER NAMES:
CN 3122: PN: WO0200677 SEQID: 3124 claimed protein
CI MAN
SQL 753

SEQ 1 AVTWCRVSSL RPLPASPYIR LRRALS LAQV DRXGASRHQR QGCEDHGRLG
51 RVTAPRGWQR AVRGGKATME LLRTITYQPA ASTKMCEQAL GKGC GADSKK
101 KRPPQPPEES QPPQSQAQVP PAAPHHHHHH SHSGPEISRI IVDPTTGKRY
151 CRGKVLGKGG FAKCYEMTDL TNNKVYAAKI IPHSRVAKPH QREKIDKEIE
201 LHRILHHKHV VQFYHYFEDK ENIYILLEYC SRRSMAHILK ARKVLTEPEV
251 RYYLRLQIVSG LKYLHEQEIL HRDLKLGNFF INEAMELKVG DFGLAARLEP
301 LEHRRRTICG TPNYLSPEVL NKQGHGCESD IWALGCVMYT MLLGRPPFET
=====

351 TNLKETYRCI REARYTMPSS LLAPAKHLIA SMLSKNPEDR PSLDDIIRHD
401 FFLQGFTPDR LSSSCCHTVP DFHLSSPAKN FFKKAAAALF GGKKDKARYI
451 DTHNRVSKED EDIYKLRHDL KKT SITQQPS KHRTDEELQP PTTTVARS GT
501 PAVENKQQIG DAIRMIVRGT LGSCSSSSEC LEDSTMGSVA DTVARVLRGC
551 LENMPEADCI PKEQLSTSFQ WVTWKVDYSN KYGFGYQLSD HTVGVLFNNG
601 AHMSLLPDKK TVHYAELGQ CSVFPATDAP EQFISQVTVL KYF SHYMEEN
651 LMDGGDLPSV TDIRRPRLYL LQWLKSDKAL MMLFNDGTFQ VNFYHDHTKI
701 IICSQNEEYL LTYINEDRIS TTFRLTLLM SGCSELKNR MEYALNMLLQ
751 RCN

HITS AT: 341-348

REFERENCE 1: 137:58696

L4 ANSWER 10 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **416847-48-8** REGISTRY
CN L-Glutamic acid, L-methionyl-L-leucyl-L-leucylglycyl-L-lysyl-L-
prolyl-L-prolyl-L-phenylalanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 47: PN: US20020049301 SEQID: 17 unclaimed sequence
SQL 9

09/736076

SEQ 1 MLLGKPPFE

HITS AT: 1-8

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:335268

L4 ANSWER 11 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN

RN 416847-41-1 REGISTRY

CN L-Glutamic acid, glycyl-L-methionyl-L-leucyl-L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 37: PN: US20020049301 SEQID: 57 unclaimed sequence

SQL 10

SEQ 1 GMLLGRPPFE

HITS AT: 2-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:335268

L4 ANSWER 12 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN

RN 416847-01-3 REGISTRY

CN L-Serine, L-methionyl-L-leucyl-L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-L- α -glutamyl-L-threonyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2: PN: US20020049301 SEQID: 19 unclaimed sequence

SQL 11

SEQ 1 MLLGRPPFET S

HITS AT: 1-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:335268

L4 ANSWER 13 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN

RN 416847-00-2 REGISTRY

CN L-Serine, L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-L- α -glutamyl-L-threonyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1: PN: US20020049301 SEQID: 18 unclaimed sequence

SQL 9

SEQ 1 LGRPPFETS

HITS AT: 1-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 136:335268

Seq. 14 A 5

Seq. 15 A 4

09/736076

L4 ANSWER 14 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **402712-46-3** REGISTRY
CN Kinase (phosphorylating), gene Snk protein (human gene Snk) (9CI)
(CA INDEX NAME)

OTHER NAMES:

CN GenBank AAC14573
CN GenBank AAC14573 (Translated from: GenBank AF059617)
CN Serum-inducible kinase (human)
CI MAN
SQL 685

SEQ 1 MELLRTITYQ PAASTKMCEQ ALGKGC GGDS KKKRPPQPPE ESQPPQSQAQ
51 VPPAAPHHHH HSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
151 DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYLRLQIV SGLKYLHEQE
201 ILHRDLKLG N FINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
251 VLNKQGHGCE SDIWALGCV M YTMLLGRPPF ETTNLKET YR CIREARYTMP
=====

301 SLLAPAKHL IASMLSKNPE DRPSLDDIIR H DFFLQGFTP DRLSSSCCHT
351 VPDFHLSSPA KNFFKKA AAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH
401 DLKTSITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGD AIRMIVR
451 GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS
501 FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKT VHYAEL
551 GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDI RRPRL
601 YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR
651 ISTTFRLTTL LMSGCSSELK NRMEYALNML LQRCN

HITS AT: 273-280

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 138:347

REFERENCE 2: 136:211644

L4 ANSWER 15 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **382721-00-8** REGISTRY
CN Kinase (phosphorylating), gene Snk protein (Xenopus laevis gene
Plx2) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN GenBank AAL30175
CN GenBank AAL30175 (Translated from: GenBank AF357840)
CN Polo-like kinase 2 (Xenopus laevis gene Plx2)
CI MAN
SQL 666

SEQ 1 MELLRNIA YQ PSSGGKMCEQ ALGRVCDPDR RWKVPGDGEP IHHSCSATDV
51 SRIITDPGTG RRYCRGKVLG KGGFAKCYEM KDLTTNKIYA AKIIPHSRVS
101 KPHQREKIDK EIELHRTL NH RHVVQFYHYF EDKENIYILM EYCGRRSMAH
151 ILKTRKVLTD PEVRYYLKQI VSGLKYLHEQ EILHRDLKLG NFFINESMEL
201 KVGDFGLAAR LEPLEQRRRT ICGTPNYLSP EVLNKQGHGC ESDIWALGCV
251 MYTMLLGRPP FETTNLKETY KCIREARYSL PSSLMTSAKH LIASMLSRNP
=====

301 EDRPSLDEIT QH DFFTQGFT PERLPTTCCH TAPDFHLSSP AKNFFKKA AAA
351 ALFGGKKEKS KYLDNHNKLP KEDEV IYKLR QGLQKNTISH QRHNPRTDEE
401 IKTISKSDVL VERADKQHMG DTIHMIVRGT LGSCSSSSEC LEDSTMGTVA
451 DTVARVLKDC LEKMPDADAI PKEQIDTSFH WVT KWVDYSN KYGFGYQLSD
501 HTVGVLFNNG AHMSFLPDKK TVHYAELGQ CSVFPATEAP EQFISQVTVL
551 KYFSHYMEEN LMDGGDLPSV TDVCRPRLYL LQWLKSDKAL MMLFNDGTFQ

09/736076

601 VNFYHDHTKI IIANQNDEYV LTYINEDRMS TTFHLSTLLI SGGSSDLKNR
651 MEYALNMLLQ RCNEVA
HITS AT: 254-261

REFERENCE 1: 136:51338

L4 ANSWER 16 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **326937-52-4** REGISTRY
CN Protein (human clone PLACE1011923) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 1057: PN: EP1074617 SEQID: 15726 claimed protein
CI MAN
SQL 469

SEQ 1 MELKVGDFGL AARLEPLEHR RRTICGTPNY LSPEVLNKQG HGCESDIWAL
51 GCVMYTMMLG RPPFETTNLK ETYRCIREAR YTMPSSLLAP AKHLIASMLS
=====
101 KNPEDRPSLD DIIRHDFFLQ GFTPDR LSSS CCHTVPDFHL SSPAKNFFKK
151 AAAALFGGKK DKARYIDTHN RVSKEDEDIY KLRHDLKKTS ITQQPSKHRT
201 DEELQPPTTT VARSGTPAVE NKQQIGDAIR MIVRGTLGSC SSSSECLEDS
251 TMGSVADTVA RVLRGCLNM PEADCIPKEQ LSTSFQWVTK WVDYSNKYGF
301 GYQLSDHTVG VLFNNGAHMS LLPDKKTVHY YAELGQCSVF PATDAPEQFI
351 SQVTVLKYFS HYMEENLMDG GDLPSVTDIR RPRLYLLQWL KSDKALMMLF
401 NDGTFQVNFY HDHTKIIICS QNEEYLLTYI NEDRISTTFR LTTLLMSGCS
451 SELKNRMEYA LNMLLQRCN
HITS AT: 57-64

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 134:188986

L4 ANSWER 17 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **220748-32-3** REGISTRY
CN Kinase (phosphorylating), protein, Snk (human) (9CI) (CA INDEX NAME)
CI MAN
SQL 685

SEQ 1 MELLRTITYQ PAASTKMCEQ ALGKGC GADS KKKRPPQPPE ESQPPQSQAQ
51 VPPAAPHHHH HSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
151 DKENIYILLE YCSRRSMAHI LKARKVLTEP EVRYYL RQIV SGLKYLHEQE
201 ILHRDLKLG N FINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
251 VLNKQGHGCE SDIWALGCV M YTMMLGRPPF ETTNLKET YR CIREARYTMP
=====
301 SLLAPAKHL IASMLSKNPE DRPSLDDIIR H DFFLQGFTP DRLSSSCCHT
351 VPDFHLSSPA KNFFKKA AAA LFGGKKDKAR YIDTHNRVSK EDEDIYKLRH
401 DLKKT SITQQ PSKHRTDEEL QPPTTTVARS GTPAVENKQQ IGD AIRMIVR
451 GTLGSCSSSS ECLEDSTMGS VADTVARVLR GCLENMPEAD CIPKEQLSTS
501 FQWVTKWVDY SNKYGFGYQL SDHTVGVLFN NGAHMSLLPD KKT VHYAEL
551 GQCSVFPATD APEQFISQVT VLKYFSHYME ENLMDGGDLP SVTDIRRPRL
601 YLLQWLKSDK ALMMLFNDGT FQVNFYHDHT KIIICSQNEE YLLTYINEDR
651 ISTTFRLTTL LMSGCSSELK NRMEYALNML LQRCN
HITS AT: 273-280

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 130:192783

09/736076

L4 ANSWER 18 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **218611-29-1** REGISTRY
CN Kinase (phosphorylating), protein (human clone 39043
disease-associated isoform DAPK-1) (9CI) (CA INDEX NAME)
CI MAN
SQL 685

SEQ 1 MELLRTITYQ PAASTKMCEQ ALGKGCAGDS KKKRPPQPPE ESQPPQSQAQ
51 VPPAAPHHHH HSHSGPEIS RIIVDPTTGK RYCRGKVLGK GGFAKCYEMT
101 DLTNNKVYAA KIIPHSRVAK PHQREKIDKE IELHRILHHK HVVQFYHYFE
151 DKENIYILLE YCSRSMMAHI LKARKVLTEP EVRYYLRLQIV SGLKYLHEQE
201 ILHRDLKLGN FFINEAMELK VGDFGLAARL EPLEHRRRTI CGTPNYLSPE
251 VLNKQGHGCE SDIWALGCV M YTMLLGRPPF ETTNLKET YR CIREARYTMP
=====

HITS AT: 273-280

REFERENCE 1: 130:77973

L4 ANSWER 19 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **216490-49-2** REGISTRY
CN L- α -Glutamine, N-(1-oxotetradecyl)glycyl-L-methionyl-L-leucyl-
L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-,
phenylmethyl ester (9CI) (CA INDEX NAME)
SQL 10

SEQ 1 GMLLGRPPFE
=====

HITS AT: 2-9

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 130:22236

L4 ANSWER 20 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **216489-81-5** REGISTRY
CN L-Serinamide, N-acetyl-L-methionyl-L-leucyl-L-leucylglycyl-L-arginyl-
L-prolyl-L-prolyl-L-phenylalanyl-L- α -glutamyl-L-threonyl-,
phenylmethyl ester (9CI) (CA INDEX NAME)
SQL 11

SEQ 1 MLLGRPPFET S
=====

HITS AT: 1-11

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 130:22236

L4 ANSWER 21 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN

☆ 3

Seq. 19

09/736076

RN 216489-79-1 REGISTRY
CN L-Serinamide, N-acetyl-L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-L- α -glutamyl-L-threonyl-, phenylmethyl ester
(9CI) (CA INDEX NAME)
SQL 9

SEQ 1 LGRPPFETS

HITS AT: 1-9

Seq. 18 Φ 2

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 130:22236

L4 ANSWER 22 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 216489-77-9 REGISTRY
CN L- α -Glutamine, N-acetyl-L-methionyl-L-leucyl-L-leucylglycyl-L-lysyl-L-prolyl-L-prolyl-L-phenylalanyl-, phenylmethyl ester (9CI)
(CA INDEX NAME)
SQL 9

SEQ 1 MLLGKPPFE

HITS AT: 1-8

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 130:22236

L4 ANSWER 23 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 216489-75-7 REGISTRY
CN L-Phenylalaninamide, N-acetyl-L-methionyl-L-leucyl-L-leucylglycyl-L-lysyl-L-prolyl-L-prolyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 12: PN: US20020049301 SEQID: 16 claimed protein
SQL 8

Seq. 16

SEQ 1 MLLGKPPF

HITS AT: 1-8

REFERENCE 1: 136:335268

REFERENCE 2: 130:22236

L4 ANSWER 24 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN 216489-73-5 REGISTRY
CN L- α -Glutamine, N-acetyl-L-methionyl-L-leucyl-L-leucylglycyl-L-arginyl-L-prolyl-L-prolyl-L-phenylalanyl-, phenylmethyl ester (9CI)
(CA INDEX NAME)
OTHER NAMES:
CN 11: PN: US20020049301 SEQID: 15 claimed protein
SQL 9

SEQ 1 MLLGRPPFE

HITS AT: 1-8

09/736076

REFERENCE 1: 136:335268

REFERENCE 2: 130:22236

L4 ANSWER 25 OF 25 REGISTRY COPYRIGHT 2003 ACS on STN
RN **148466-70-0** REGISTRY
CN Kinase (phosphorylating), protein (mouse clone 2 isoenzyme Snk
reduced) (9CI) (CA INDEX NAME)
CI MAN
SQL 682

SEQ 1 MELLRTITYQ PAAGTKMCEQ ALGKACGGDS KKKRPQQPSE DGQPQAQVTP
51 AAPHHHHHHS HSGPEISRRII VDPTTGKRYC RGKVLGKGGF AKCYEMTDLT
101 NNKVYAAKII PHSRVAKPHQ REKIDKEIEL HRLHHKHVV QFYHYFEDKE
151 NIYILLEYCS RRSMAHILKA RKVLTEPEVR YYLRQIVSGL KYLHEQEILH
201 RDLKLGNIFFI NEAMELKVG D FGLAARLEPL EHRRRTICGT PNYLSPEVLN
251 KQGHGCESDI WALGCVMYTM LLGRPPFETT NLKETYRCIR EARYTMPSSL
= =====
301 LAPAKHLIAS MLSKNPEDRP SLDDIIRHDF FLQGFTPDLR SSSCCHTVPD
351 FHLSSPAKNF FKKAAAALFG GKDKARYND THNKVSKED DIYKLRHDLK
401 KVSITQQPSK HRADEEPQPP PTTVARSGTS AVENKQQIGD AIRMIVRGTL
451 GSCSSSSECL EDSTMGSVAD TVARVLRGCL ENMPEADCIP KEQLSTSFQW
501 VTKWVDYSNK YGFGYQLSDH TVGVLFNNGA HMSLLPDKKT VHYYAELGQC
551 SVFPATDAPE QFISQVTVLK YFSHYMEENL MDGGDLPSVT DIRRPRLYLL
601 QWLKSDKALM MLFNDGTFQV NFYHDHTKII ICNQSEEYLL TYINEDRIST
651 TFRLLTLLMS GCSLELKNRM EYALNMLLQR CN

HITS AT: 270-277

RELATED SEQUENCES AVAILABLE WITH SEQLINK

REFERENCE 1: 119:44118

FILE 'HOME' ENTERED AT 14:29:31 ON 14 NOV 2003